Ben is a senior associate in our IP and commercial group, with a particular focus on the technology and life sciences sectors.
Ben advises clients on cross-border transactions involving valuable technology, IP and data, particularly in the context of international tech and life sciences M&A, carve-outs, JVs and financing. Ben regularly advises on complex commercial and IP agreements, including licensing/collaboration arrangements, manufacturing, supply and other related commercial agreements.
Ben also advises clients on the full range of legal issues relating to data, including IP protection and data privacy matters, particularly in the context of deals, crises, and new data uses and analytics including AI. He has completed a professional training programme in AI at Oxford University.
Ben has contentious experience and advises clients on the litigation/arbitration of patents, software and IP/technology licences.
- EQT on its agreement to acquire a majority stake in Adalvo, a leading asset-light B2B dossier developer.
- Advent on its $4.8 billion sale of Zentiva, a leading European generics pharmaceutical company, to GTCR.
- Moderna on its ten-year agreement with the UK Government to establish a state-of-the-art, domestic mRNA manufacturing facility in the UK.
- Novartis on the $12 billion separation and spin-off of Sandoz, its generics and biosimilars division.
- SERB Pharmaceuticals on its agreement to acquire Y-mAbs Therapeutics, Inc.
- Bio-Rad on its binding offer to acquire all the equity interest in French Digital PCR Developer Stilla Technologies.
- A biopharmaceutical company on its technology licence agreement with multinational pharmaceutical and biotechnology corporation, covering the in-licensing of an antibiotic.
- An international medTech company on its licence agreement with an international skincare company.
- An international drug delivery solutions company on its global distribution agreement with a leading medical technology company.
- Hasten Biopharmaceuticals on its acquisition of the product portfolios in South East Asia from Celltrion Healthcare.
- Recordati, a portfolio company of CVC Capital Partners, on its acquisition of EUSA Pharma (UK) Limited.
- A West Coast tech company on strategic acquisitions of digital content and AI-related software businesses across Europe from founders and funders.
- A global alternative asset manager on its acquisition of a data analytics and consulting company.
- General Atlantic's BeyondNetZero on the acquisition of a minority stake in ABB E-mobility, valuing the company at $2.6 billion
- RELX, a global provider of information-based analytics and decision tools for professional and business customers, on its acquisition of a software business relating to validating bank payments.
- Advising and assisting major companies, financial institutions and their insurers, manage their response to major cyber incidents, including dealing with multiple regulators and affected individuals.
- Advising leading financial institution, West Coast tech company, international oil and gas company and UK Government Authority on data privacy and cyber legal issues and risks.
- Mumtalakat on the IP and commercial agreements in connection with the sale of McLaren Automotive and a non-controlling stake in McLaren Racing.
- Universal Music Group on the IP aspects of its majority Investment in Mavin Global.
- Rolls-Royce on the IP aspects of its major strategic partnership with CEZ to build Small Modular Reactors in the Czech Republic.
- Suzano on the IP aspects of its $3.4 billion joint venture with Kimberly-Clark to create a new global tissue company.
- EdF on the IP aspects of its acquisition of part of GE Steam Power’s nuclear power business.
- AstraZeneca on its cancer drug patent licence dispute with Tesaro.
- A biotechnology and food company on its ICC arbitration with a bioscience company, relating to a genetically engineered food product.
- A European financial institution on a dispute with a fintech company relating to a technology license.
100 Bishopsgate